Get the Stockscreener App
377.00
2.26%
-8.70
After Hours:
378.59
1.59
+0.42%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $377.00, with a volume of 2.71M.
It is down -2.26% in the last 24 hours and up +11.34% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$385.70
Open:
$377.97
24h Volume:
2.71M
Relative Volume:
0.96
Market Cap:
$203.23B
Revenue:
$36.74B
Net Income/Loss:
$7.71B
P/E Ratio:
26.49
EPS:
14.2333
Net Cash Flow:
$8.10B
1W Performance:
-1.53%
1M Performance:
+11.34%
6M Performance:
+32.82%
1Y Performance:
+21.31%
1-Day Range:
$372.71
$381.74
1-Week Range:
$372.71
$391.29
52-Week Range:
$261.43
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, NVS, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
377.00 | 207.92B | 36.74B | 7.71B | 8.10B | 14.23 |
|
LLY
Lilly Eli Co
|
1,007.73 | 909.04B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
246.75 | 599.00B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
233.86 | 414.21B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
NVS
Novartis Ag Adr
|
164.18 | 318.41B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
201.76 | 315.94B | 58.80B | 10.24B | 8.98B | 3.2788 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen EVP Sold $20.77M In Company Stock - Benzinga
Amgen stock forecast for 2030: $6B patent exposure challenges $500 level - Traders Union
Amgen (NASDAQ:AMGN) Sets New 1-Year HighShould You Buy? - MarketBeat
Amgen (NASDAQ:AMGN) Hits Annual High Within The Nasdaq 100 Index Rally - Kalkine Media
Amgen Touts Broad Portfolio Momentum, MariTide Milestones and Repatha Access Push at TD Cowen Conf - Yahoo Finance
IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook - Stocktwits
Amgen Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S Revenue Breakdown – NEO:AMGN - TradingView
How North Carolina Attracted Amgen and Roche To Become a Next-Gen Obesity Drug Production Hotspot - BioSpace
Amgen (AMGN) EVP Esteban Santos exercises options and sells 54,792 shares - Stock Titan
Amgen at TD Cowen Conference: Strategic Growth and Challenges - Investing.com India
Amgen Is Up 35% in the Last 6 Months. Here’s Where the Stock Could Go in 2026 - TIKR.com
Amgen’s Phase 3 Gout Trial Pits Subcutaneous Pegloticase Against IV Dosing - TipRanks
A Couple's Financial Manifesto, Revisited - The Motley Fool
Amgen Inc. (AMGN) Stock Report: Evaluating the 106% Return on Equity and Market Prospects - DirectorsTalk Interviews
Laurel Wealth Advisors LLC Cuts Position in Amgen Inc. $AMGN - MarketBeat
Bahl & Gaynor Inc. Lowers Stock Holdings in Amgen Inc. $AMGN - MarketBeat
6,843 Shares in Amgen Inc. $AMGN Purchased by 111 Capital - MarketBeat
AMGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Amgen Deployed a Record $7.2 Billion in R&D: Here’s What Investors Should Expect - TIKR.com
How Amgen’s $4 Billion Long-Dated Bond Issuance At Amgen (AMGN) Has Changed Its Investment Story - Yahoo Finance
Amgen Recasts Growth Story With Product Momentum And Long Dated Funding - simplywall.st
Amgen Inc. (AMGN): A Bull Case Theory - Insider Monkey
Harvest Portfolios Group Inc. Boosts Holdings in Amgen Inc. $AMGN - MarketBeat
Argent Trust Co Lowers Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Stock Holdings Boosted by Allianz SE - MarketBeat
Insider plans sale of 54,792 AMGN shares (NASDAQ: AMGN) - Stock Titan
Amgen Advances Maridebart Cafraglutide Toward Mid-Stage Obesity and Liver Fat Trial - TipRanks
Amgen Fine-Tunes Evolocumab: New Bioavailability Study Signals Long-Term Cholesterol Franchise Focus - TipRanks
Amgen Nears a Nivolumab Biosimilar Milestone in Melanoma: What Investors Should Watch - TipRanks
Amgen Inc. $AMGN Shares Purchased by Sumitomo Mitsui Financial Group Inc. - MarketBeat
Handelsbanken Fonder AB Sells 47,932 Shares of Amgen Inc. $AMGN - MarketBeat
Intech Investment Management LLC Has $13.65 Million Position in Amgen Inc. $AMGN - MarketBeat
Erste Asset Management GmbH Decreases Position in Amgen Inc. $AMGN - MarketBeat
Empirical Asset Management LLC Has $306,000 Position in Amgen Inc. $AMGN - MarketBeat
US Bancorp DE Has $194 Million Holdings in Amgen Inc. $AMGN - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Boosts Stock Position in Amgen Inc. $AMGN - MarketBeat
Primecap Management Co. CA Decreases Stock Position in Amgen Inc. $AMGN - MarketBeat
TD Asset Management Inc Has $108.85 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen (NASDAQ:AMGN) Sets New 52-Week HighHere's What Happened - MarketBeat
Amgen stock hits all-time high at 385.63 USD - Investing.com South Africa
Is Amgen Stock Outperforming the Dow? - Barchart.com
MAI Capital Management Has $21.81 Million Holdings in Amgen Inc. $AMGN - MarketBeat
RWA Wealth Partners LLC Increases Holdings in Amgen Inc. $AMGN - MarketBeat
Evaluating Amgen (AMGN) After Barclays Coverage And Strong Q4 2025 Portfolio Momentum - simplywall.st
Amgen (NASDAQ: AMGN) withdraws listing for 2.000% Senior Notes due 2026 - Stock Titan
How to watch Amgen's TD Cowen health-care conference webcast - Stock Titan
Technical Analysis of Amgen Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S (NEO:AMGN) - TradingView
Amgen Inc. $AMGN Shares Sold by M. Kulyk & Associates LLC - MarketBeat
Dakota Wealth Management Has $9.15 Million Holdings in Amgen Inc. $AMGN - MarketBeat
EverSource Wealth Advisors LLC Has $5.40 Million Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen’s New UPLIZNA Nod and $4 Billion Bond Sale Might Change The Case For Investing In Amgen (AMGN) - simplywall.st
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):